Unique ID issued by UMIN | UMIN000048852 |
---|---|
Receipt number | R000055625 |
Scientific Title | Development of a biomarker of fibromyalgia on neuroinflammation. |
Date of disclosure of the study information | 2022/09/12 |
Last modified on | 2024/03/11 12:15:22 |
Development of a biomarker of fibromyalgia on neuroinflammation.
Development of a biomarker of fibromyalgia on neuroinflammation.
Development of a biomarker of fibromyalgia on neuroinflammation.
Development of a biomarker of fibromyalgia on neuroinflammation.
Japan |
Fibromyalgia, chronic pain
Neurology | Clinical immunology | Psychosomatic Internal Medicine |
Psychiatry | Orthopedics | Adult |
Others
NO
To investigate the relationship between fibromyalgia and complement.
Others
Validation as biomarkers
Concentration of complement (C3a, C5a, sC5b-9) in peripheral blood.
The relationship between the concentration of complement and clinical features such as psychological and physiological measurements.
Observational
18 | years-old | <= |
Not applicable |
Male and Female
[Fibromyalgia]
(1) Patients diagnosed with fibromyalgia.
(2) Patients who fully understand this research plan and can give their consent.
(3) Patients who are at least 18 years of age at the time consent is obtained.
[Chronic pain]
(1) Patients who have pain that lasts more than 3 months but do not meet the diagnostic criteria for fibromyalgia.
(2) Patients who fully understand this research plan and can give their consent.
(3) Patients who are at least 18 years of age at the time consent is obtained.
[Healthy control]
(1) Healthy subjects who do not have pain lasting more than 3 months.
(2) Persons who fully understand this research plan and can give their consent.
(3) Persons who are at least 18 years of age at the time consent is obtained.
[Fibromyalgia]
(1) Patients with symptoms of anemia (hemoglobin 8 g/dl or less)
(2) Patients with poor general condition (PS value >3)
(3) Patients diagnosed with autoimmune disease, chronic infectious disease, demyelinating disease, complement-related disease (PNH, NMO, MS), malignant disease
(4) Other patients deemed by the investigator to be inappropriate as research subjects.
[Chronic pain]
(1) Patients with symptoms of anemia (hemoglobin of 8 g/dl or less)
(2) Patients with poor general condition (numerical value: PS value 3 or higher)
(3) Those diagnosed with autoimmune disease, chronic infectious disease, demyelinating disease, complement-related disease (PNH, NMO, MS), or malignant disease
(4) Other subjects deemed by the investigator to be inappropriate as research subjects.
[Healthy control]
(1) Those with symptoms of anemia (hemoglobin 8 g/dl or less)
(2) Patients with poor general condition (PS value of 3 or higher)
(3) Patients receiving treatment for pain
(4) Those diagnosed with autoimmune disease, chronic infectious disease, demyelinating disease, complement-related disease (PNH, NMO, MS), or malignant disease
(5) Any other person whom the investigator deems inappropriate as a research subject.
80
1st name | Masako |
Middle name | |
Last name | HOSOI |
Kyushu University
Department of Psychosomatic Medicine, Graduate School of Medical Sciences.
812-8582
3-1-1, Maidashi, Higashi-ku, Fukuoka City
092-642-5320
hosoi.masako.642@m.kyushu-u.ac.jp
1st name | Koji |
Middle name | |
Last name | FUJIMOTO |
Kyushu University
Department of Psychosomatic Medicine, Graduate School of Medical Sciences.
812-8582
3-1-1, Maidashi, Higashi-ku, Fukuoka City
092-642-5320
fujimoto.koji.059@m.kyushu-u.ac.jp
Department of Psychosomatic Medicine, Graduate School of Medical Sciences, Kyushu University
Japan Society for the Promotion of Science
Japanese Governmental office
Kyushu University Institutional Review Board for Clinical Research
3-1-1, Maidashi Higashi-ku, Fukuoka, 812-8582, Japan
092-642-6254
ijkseimei@jimu.kyushu-u.ac.jp
NO
2022 | Year | 09 | Month | 12 | Day |
Unpublished
Enrolling by invitation
2022 | Year | 03 | Month | 18 | Day |
2022 | Year | 08 | Month | 10 | Day |
2022 | Year | 09 | Month | 12 | Day |
2027 | Year | 02 | Month | 28 | Day |
This study will clarify the relationship between fibromyalgia and complemental system. We will examine whether peripheral complement levels are elevated in patients with fibromyalgia compared to controls, as well as the validity of complement as a biomarker for diagnosis and severity by examining clinical features.
2022 | Year | 09 | Month | 05 | Day |
2024 | Year | 03 | Month | 11 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000055625
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |